Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases-A prospective randomised placebo-controlled multicentre study
In a double blind randomised multicentre study the effect of intravenous clodronate plus hydration was compared with placebo plus hydration in the treatment of hypercalcaemia in breast cancer patients with bone metastases. The patients were treated either with hydration plus clodronate 300 mg/day or hydration plus placebo, up to 7 days or until serum ionised calcium was below 1.4 mmol/l. 25 patien